Introduction {#sec1}
============

Myocardial protection during open heart surgery has been the focus of clinical research for many decades, but the debate regarding the ultimate cardioprotective strategy and the search for the ideal cardioplegic solution are still ongoing. In the early 1990s, Dr. Pedro del Nido and his team at the University of Pittsburgh developed a cardioplegic solution to address the specific needs of immature myocardium encountered in neonatal and pediatric cardiac surgery. The solution, now commonly referred to as del Nido (DN) cardioplegia, induces a depolarizing arrest during cardiac surgery. It is more dilute (1 : 4, blood : crystalloid) as compared to the traditional 4 : 1 blood cardioplegia; it has less Ca^2+^ and contains lidocaine \[[@cit0001]\] ([Tab. I](#t0001){ref-type="table"}).

###### 

Composition of St Thomas (ST) and del Nido (DN) cardioplegia solutions

  ST cardioplegia                 
  ------------------------------- ----------------------
  Na^+^                           110 mmol/l
  K^+^                            16 mmol/l
  Mg^2+^                          16 mmol/l
  Ca^2+^                          1.2 mmol/l
  NaHCO~3~^--^                    10 mmol/l
  **DN cardioplegia**             
  Mannitol                        20%, 16.3 ml, 3.26 g
  Magnesium sulfate               50%, 4 ml, 2 g
  Sodium bicarbonate              8.4%, 13 ml, 13 mEq
  Lidocaine                       1%, 13 ml, 130 mg
  Potassium chloride (2 mEq/ml)   13 ml, 26 mEq

St. Thomas' cardioplegic solution No. 2 (ST) has been a popular crystalloid cardioplegia among cardiac surgeons; however, it must be administered repeatedly at short intervals during the surgery. Increases in myocardial acidosis between the doses have been noted, affecting the postoperative outcome adversely \[[@cit0002], [@cit0003]\]. Thus, it would be beneficial if the interval between the cardioplegic doses could be increased, thereby reducing the number of doses required during surgery. The DN's potential practical advantage is the fact that it provides a long period of arrest before a subsequent dose is needed \[[@cit0004]\]. Investigators have begun reporting their clinical experiences with DN in adult hearts and have achieved good outcomes with a single dose or longer intervals between doses, leading to shorter cross-clamp times \[[@cit0005]--[@cit0008]\].

Aim {#sec2}
===

The aim of this study is to evaluate the efficacy and safety of DN as compared to ST in adults undergoing elective coronary artery bypass grafting (CABG) and double valve replacement (DVR) surgery. We decided to include the longer DVR procedure as few cases requiring prolonged cardiac arrest using the DN solution have been included in previous studies.

Material and methods {#sec3}
====================

Patient population {#sec3.1}
------------------

This retrospective study was conducted at the Department of Cardiovascular and Thoracic Surgery of Lokmanya Tilak Municipal Medical College & Sion Hospital. Consecutive patients undergoing elective CABG or DVR surgery were retrospectively studied from January 2015 to January 2016; they were divided into two cohorts based on the type of cardioplegia administered during surgery: 1) intermittent St. Thomas' No. 2 cardioplegia (ST, *n* = 50) used in patients from January 2015 until June 2015, and 2) del Nido cardioplegia (DN, *n* = 50) used from June 2015 to January 2016. Demographic details and clinical outcome data were retrospectively collected from patient files and our department's computerized patient records; they included patient age, sex, comorbid medical conditions such as diabetes, hypertension, etc., as well as preoperative left ventricular ejection fraction (LVEF). The intra- and postoperative details collected for the two cohorts included cardiopulmonary bypass (CPB) time, aortic cross clamp (CC) time, the number of cardioplegia doses, intraoperative DC shocks required, postoperative LVEF, and in-hospital mortality.

Cardioplegia administration {#sec3.2}
---------------------------

All procedures were performed using a standard general anesthesia protocol, median sternotomy approach, and cardiopulmonary bypass with mild systemic hypothermia (30 to 34°C). Myocardial protection was achieved with either ST or DN cardioplegia as follows. In both groups, the heart was arrested with an induction dose (1 l) of cold (4°C) cardioplegia using antegrade and/or retrograde delivery ([Tab. I](#t0001){ref-type="table"}). In addition, repeated doses of ST cardioplegia were given to ST patients only. A second dose (500 ml) of DN was provided only when the cross clamp time exceeded 90 min.

Statistical analysis {#sec3.3}
--------------------

The data were analyzed using SPSS version 10. Continuous variables were reported as mean ± standard deviation and compared using the independent samples *t*-test. Categorical variables were reported as frequency and percentage of the total group and compared using Pearson's χ^2^ test or Fisher's exact test where applicable. All *p*-values ≤ 0.05 were considered significant.

Results {#sec4}
=======

Baseline demographics {#sec4.1}
---------------------

A total of 100 patients were studied: 50 in the St. Thomas' No. 2 group (ST group) and 50 in the del Nido group (DN group). Thirty-four (68%) patients underwent CABG in the ST group as compared to 36 (72%) patients in the DN group, while DVR was performed in 16 (32%) and 14 (28%) patients in the ST and DN groups, respectively. The overall mean age of the patients was 51.86 ±13.4 years (range: 16--74 years). All other demographic characteristics of the patients in the two study groups were similar, as shown in [Table II](#t0002){ref-type="table"}.

###### 

Baseline demographics

  --------------------------------------------------------------------
  Variable                 ST              DN              *P*-value
  ------------------------ --------------- --------------- -----------
  Total *n*                50              50              

  CABG, *n* (%)            34 (68)         36 (72)         

  DVR, *n* (%)             16 (32)         14 (28)         

  Age \[years\]            50.96 ±14.13    52.48 ±13.05    0.657

  Gender (male), *n* (%)   39 (78)         37 (74)         0.639

  Diabetes, *n* (%)        41 (82)         40 (80)         0.798

  Hypertension, *n* (%)    43 (86)         41 (82)         0.585

  LVEF (%, mean ± SD):\     \               \               \
   Total\                  53.80 ±09.60\   50.00 ±12.86\   0.195\
   CABG\                   50.31 ±10.56\   47.22 ±13.03\   0.308\
   DVR                     60.00 ±0.00     57.77 ±10.77    0.305
  --------------------------------------------------------------------

Intra- and postoperative variables and outcomes {#sec4.2}
-----------------------------------------------

The intra- and postoperative outcome details are presented in [Table III](#t0003){ref-type="table"}. The aortic cross clamp and cardiopulmonary bypass times during both CABG and DVR surgery using del Nido cardioplegia were significantly reduced as compared to the ST group. Additionally, the administration of DN cardioplegia resulted in a significantly lower number of required doses as compared to the ST group (1.38 ±0.59 vs. 4.15 ±1.26; *p* = 0.001). A single cardioplegia dose was given to 35 (70%) DN patients, while ST patients required at least 2 (and up to a maximum of 7) doses of cardioplegia. There was no significant difference between the two groups in the percentage of cases in which intraoperative DC shocks were required.

###### 

Intra- and postoperative profile

  ----------------------------------------------------------------------------------------------------------------------
  Variable                                             Procedure   ST                   DN                   *P*-value
  ---------------------------------------------------- ----------- -------------------- -------------------- -----------
  Number of grafts                                     CABG        3.8 ±0.67            4 ±0.62              0.310

  Aortic cross clamp time, mean ± SD \[min\]           Total\      133.56 ±35.66\       110.15 ±36.84\       0.012\
                                                       DVR\        152.11 ±24.99\       128.77 ±22.74\       0.034\
                                                       CABG        128.28 ±37.11        104.22 ±38.50        0.043

  Cardiopulmonary bypass time, mean ± SD \[min\]       Total\      179.81 ±42.36\       158.60 ±39.92\       0.041\
                                                       DVR\        198.78 ±27.87\       177.69 ±17.30\       0.040\
                                                       CABG        172.83 ±46.07        143.85 ±45.39        0.043

  Number of doses of cardioplegia, mean ± SD (range)   Total\      4.15 ±1.26 (2--7)\   1.38 ±0.59 (1--3)\   0.001\
                                                       DVR\        4.78 ±1.39 (2--7)\   1.46 ±0.66 (1--3)\   0.001\
                                                       CABG        3.83 ±1.10 (2--6)    1.33 ±0.55 (1--3)    0.001

  Intraoperative DC shocks required, *n* (%)           Total\      2 (4)\               2 (4)\               1.000\
                                                       DVR\        1 (6.2)\             1 (7.1)\             0.922\
                                                       CABG        1 (2.9)              1 (2.7)              0.967

  Inotropic usage, *n* (%)                             Total\      26 (52)\             23 (46)\             0.548\
                                                       DVR\        14 (87.5)\           12 (85.7)\           0.885\
                                                       CABG        12 (35.2)            11 (30.5)            0.817

  IABP usage, *n* (%)                                  Total\      1 (2)\               0\                   0.314\
                                                       DVR\        0\                   0\                   1.000\
                                                       CABG        1 (2.9)              0                    0.300

  In-hospital mortality, *n* (%)                       Total\      1 (2)\               0\                   0.314\
                                                       DVR\        0\                   0\                   1.000\
                                                       CABG        1 (2.9)              0                    0.300
  ----------------------------------------------------------------------------------------------------------------------

Twenty-six (52%) patients in the ST group and 23 (46%) patients in the DN group needed inotropic drug support during the time between aortic declamping and being transported to the intensive care unit. The difference between the two groups was not statistically significant (*p* = 0.72). In the ST group, one CABG patient required intraoperative intra-aortic balloon counterpulsation (IABP).

Postoperatively, the overall mean LVEF showed a significant fall of 3.3% among the ST group and an insignificant rise of 2.5% among the DN group in comparison with the pretreatment values. When compared, the change was significantly more pronounced in the ST group than in the DN group. This change in LVEF was mainly observed in the CABG group, as presented in [Table IV](#t0004){ref-type="table"}. Although this information was not routinely recorded, we did not observe any noticeable intergroup differences in the time to restoration of cardiac rhythm or time to weaning from bypass.

###### 

Comparison of changes in mean LVEF between the groups by procedure

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Procedure   Mean LVEF      *P*-value                                                                                                                                  
  ----------- -------------- -------------- ----------------------------------------------- -------------- -------------- --------------------------------------------- ----------------------------------------
  Total       53.80 ±9.60    52.00 ±10.41   --1.80 ±4.05[\*](#tf4-1){ref-type="table-fn"}   50.00 ±12.86   51.25 ±11.02   1.25 ±7.99                                    0.046[\*](#tf4-1){ref-type="table-fn"}

  DVR         60.00 ±0.00    58.89 ±2.20    --1.11 ±2.20[\*](#tf4-1){ref-type="table-fn"}   57.77 ±10.77   54.69 ±12.18   --3.08 ±10.32                                 0.248\
                                                                                                                                                                        NS

  CABG        50.31 ±10.56   48.13 ±11.24   --2.18 ±4.82[\*](#tf4-1){ref-type="table-fn"}   47.22 ±13.03   50.56 ±10.59   3.34 ±5.72[\*](#tf4-1){ref-type="table-fn"}   0.001[\*](#tf4-1){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NS -- not significant

significant.

In-hospital mortality was higher in the ST group, but the difference was not statistically significant (*p* = 0.314). One (2%) patient in the ST group died during CABG due to profound cardiogenic shock; there was no hospital mortality in the DN group.

Discussion {#sec5}
==========

Cardioplegic solutions have a key role in protecting the heart from myocardial injury during open heart surgery. The DN solution has been used successfully in pediatric cardiac surgery \[[@cit0001], [@cit0004], [@cit0009]\]; however, its use in adult cardiac surgery has only recently been described \[[@cit0005]--[@cit0008]\]. The proposed benefit of this solution is the avoidance of the need for repetitive interruption of the procedure to administer multiple doses of standard cardioplegia, which leads to shorter cross clamp times. In this study, we present our experience with DN cardioplegia in patients undergoing elective CABG or DVR and compare it with our cohort of patients who received ST cardioplegia.

Shorter CC and CPB times in the operations utilizing DN were the primary findings apparent from our study, which is consistent with earlier studies using DN in adult patients \[[@cit0005], [@cit0007], [@cit0008]\]. This can be attributed to the reduced requirement to administer repeated doses of cardioplegia. The CC and CPB times in the present study were, however, longer than those reported in previously published studies in adult patients. This was expected due to the inclusion of longer procedures (DVR and CABG with multiple grafting) in our study. A single dose of cardioplegia was administered to 70% of our patients in the DN group, with the rates reported in adult studies from different centers ranging from 40% to 84% \[[@cit0005], [@cit0007]\]. The lower rate of 40% reported by Smigla *et al.* can be attributed to their re-dosing policy of 45 min as compared with 90 min in our study. Less frequent dosing allows the surgeon to operate uninterrupted and decreases the risk of contamination. These advantages of DN may facilitate myocardial protection during adult cardiac surgery.

Lower rates of immediate postoperative complications and mortality with the use of DN were observed in our data, but the differences did not reach statistical significance. Nonetheless, superior protection of DN over ST and a comparable safety profile can be predicted from the improved postoperative LVEF in the DN group noted in our study. Accelerated accumulation of intracellular Ca^2+^ during myocardial ischemia mediates the early reperfusion injury that occurs during cardiac surgery \[[@cit0010]--[@cit0012]\]. The myocardial cell counteracts this high intracellular Ca^2+^ through energy requiring active transport mechanisms and ultimately manifesting as myocardial dysfunction upon reperfusion. The DN contains lidocaine, a membrane-stabilizing agent which increases Na^+^ channel blockade and minimizes the potential for a Na^+^ window current. Together with its Mg^2+^ content acting as a Ca^2+^ antagonist, these are the suggested mechanisms by which DN cardioplegia protects the myocardium from high intracellular Ca^2+^ \[[@cit0009]\].

O'Blenes *et al.* previously reported that, in isolated aged rat cardiomyocytes, cardiac arrest with DN cardioplegia resulted in lower spontaneous activity during ischemia, lower diastolic Ca^2+^ during ischemia and reperfusion, and avoidance of Ca^2+^-induced hypercontraction during early reperfusion in comparison with standard cardioplegia \[[@cit0012]\]. Later, they also showed that, in a similar setting of aged hearts, single-dose DN cardioplegia was also associated with superior calcium handling of cardiomyocytes, reduced myocardial injury, and improved functional recovery \[[@cit0013]\]. However, these findings need to be confirmed using more clinically relevant methodology, and their effect on long-term post-operative ventricular function should be examined.

Limitations of the study {#sec5.1}
------------------------

The limitations of our study include its retrospective, descriptive nature and small cohort size. Moreover, only postoperative hemodynamic parameters were used to assess myocardial protection, while biochemical parameters such as postoperative cardiac enzymes could have enabled better analysis of direct cardiac injury. Finally, no long-term follow-up of myocardial protection (e.g., changes in regional wall motion or ejection fraction) was performed. More prospective long-term studies must be designed to explore the applications of DN cardioplegia and to validate our current findings.

Conclusions {#sec6}
===========

Our study showed that the use of DN cardioplegia reduced the time of CC and CPB as well as the need for repeated doses of cardioplegia. Additionally, it provided potentially better myocardial protection in view of the preserved LVEF values, with a safety profile and mortality comparable to ST cardioplegia. To our knowledge, our data are the first to show that DN cardioplegia is a beneficial alternative to ST cardioplegia even in longer procedures such as DVR.
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